Background/Aim-The reliability of a quantitative method for the non-invasive assessment of intestinal disaccharide hydrolysis was assessed.
g 5421, 200 mg) together with sucrose and lactulose increased the urinary sucrose/ lactulose excretion ratios (°/0 dose/10 h) fivefold. The effect was quantitatively reproducible, a higher dose of 'Acarbose' (500 mg) increasing the excretion ratio to about 1.0 indicating complete inhibition of intestinal sucrase activity. The suitability ofthe method for measuring differences in dose/response and duration of action was assessed by comparing three different a-glucosidase inhibitors (BAY g 5421, BAY m 1099, and BAY o 1248) and found to be satisfactory. Subjects with primary adult hypolactasia had urine lactose/ lactulose excretion ratios raised to values indicating reduced rather than complete absence of lactase activity whereas sucrose/lactulose ratios were not significantly affected. ' Whole' intestinal disaccharidase activity assessed by this method demonstrated impairment of lactase, sucrase, and isomaltase in eight, one, and seven, respectively, of 20 patients with coeliac disease. By contrast in vitro assay of jejunal biopsy tissue indicated pandisaccharidase deficiency in all but five of these patients. This shows the importance of distinguishing between 'local' and 'whole' intestinal performance. Conclusions-Differential urinary excretion of ingested disaccharides provides a reliable, quantitative, and non-invasive technique for assessing profiles of intestinal disaccharidase activity. (Gut 1996; 39: 374-381) Keywords: coeliac disease, intestinal function, intestinal disaccharidases, intestinal permeability.
Intestinal disaccharidase deficiency, either primary or secondary, is a frequent cause of gastrointestinal symptoms and it is reported that as many as 50% to 90% of adult non-white subjects may be lactase deficient.' Conventional non-invasive assessment of intestinal disaccharidase deficiency is open to some criticism. The oral lactose tolerance test entails ingestion of non-physiological quantities of lactose (50-100 g, equivalent to 1-2 litres of milk) or other disaccharide, often accompanied by unpleasant symptoms. 4 The test has a high false positive rate, thus a rise in blood glucose below 20 mg/100 ml (1.1 mmol/l), which is taken to indicate disaccharidase deficiency4 may have alternative explanations. The high false positive rate can be reduced somewhat by intra-duodenal instillation of disaccharide but at the cost of losing the non-invasive nature of the procedure.5 Alternatively, with respect to hydrolysis of lactose, it has been suggested that measurement of the rise of blood galactose might be preferable to that of glucose.6 Furthermore, as renal excretion of galactose is efficient, some authors have advocated the measurement of galactose, or of a lactose/ galactose ratio, in urine after ingestion of lactose.7 8 Methods involving breath hydrogen or`C-labelled carbon dioxide after ingestion of appropriate disaccharide test doses5 9 10 are beset with somewhat similar problems. Difficulties with these techniques are in part because the uptake and metabolism of monosaccharide products, or generation of hydrogen in the bowel depend upon several other variable factors beside the rate of hydrolysis by brush border disaccharidases. ' 11-13 Diagnosis of disaccharidase deficiency can also be made by in vitro assay of homogenised jejunal tissue. It is necessary to consider, however, how well these assays represent the in vivo performance of the whole intestine, especially in coeliac disease where the severity of the disease is usually maximal in the proximal jejunum,4 ileal functions being comparatively unaffected.
A further non-invasive technique has been proposed that avoids error due to variations in monosaccharide transport and metabolism, and may therefore permit a more specific and quantitative assessment of intestinal disaccharidase activity. 1 ,B-D-fructofuranoside) and 6-7 g lactulose (, [1] [2] [3] [4] galactopyranosyl-fructose= 10 ml 'Duphalac' lactulose syrup, Duphar Laboratories, Southampton) dissolved in 300 ml water (300 mmol/l) was ingested within a period of four minutes. Food and fluids were not permitted until 2-5 hours later. A complete urine collection was made from 8 am to 6 pm (10 hours), the volume recorded, and an aliquot preserved with merthiolate (10 mg/100 ml minimum) for analysis of sugars by quantitative paper or thin layer chromatography." 17 18 Eleven patients with symptomatic, untreated, and nine with treated coeliac diseases were studied, the latter having achieved a full clinical recovery with a gluten free diet of mean duration six years (range nine months-1 2 years). The mean age of the whole group was 54 years (range 28-74). Each patient was admitted to a metabolic research ward for investigation, in vivo studies and jejunal biopsies being performed within a week of each other.
Assessment of intestinal disaccharide hydrolysis by urinary excretion ratio Dietary sources of sucrose, lactose, and lactulose were excluded for 18 hours before and throughout the test period. Each subject fasted overnight and voided urine directly before the test, a 'baseline' urine being retained to exclude the presence of disacchariduria. At 8 am each subject ingested a 300 ml test solution containing: Lactose: 10 g (to assess lactase activity), Sucrose: 10 g (to assess sucrase activity), Palatinose: 10 g (to assess palatinase (isomaltase) activity (cx-1-6 D glucopyranosyl-D-fructofuranose, isomaltulose), Lactulose: 6.7 g (as non-hydrolysable reference for disaccharide permeation, also to assess 'large pore' permeation), L-rhamnose: 1 g (to assess 'small pore' permeability).
Incorporation of L-rhamnose permits simultaneous assessment of intestinal permeability by measurement of lactulose-/L-rhamnose urine excretion ratios, but as the data from this study did not expand on the already extensive published literature these results are not presented. '3 Foods and fluids were permitted 2.5 hours after ingestion of the test solution.
Urine was collected for 0-5 and 5-10 hours, with merthiolate (10 mg/100 ml) as a preservative, for marker analysis as described. '7 18 Assessment of intestinal disaccharide activity by in vitro assay
Intestinal biopsy specimens were obtained by intubation technique with an adult Watson biopsy capsule, under radiological guidance, just distal to the ligament of Trietz. A portion of the biopsy specimen was allocated for histological examination, the remainder being Figure 2 shows the 10 hour urine sucrose/ lactulose excretion ratios obtained when the test solution had been ingested without, and then together with progressively increasing doses ofthe three aL-glucosidase inhibitors. The normal control 10 hour sucrose/lactulose excretion ratio (mean SD)) was 0*12 (0. 10), range 0 05-0 30).
With increasing amounts of simultaneously ingested BAY g 5421 (Acarbose 25-500 mg) there was stepwise and significant (p<0.01) increase in urine excretion ratio of sucrose/ lactulose with a mean of 0.61 (0.12) and 0.91 (0.09) for 200 and 500 mg BAY g 5421, respectively. Ingestion of the two other a-glucosidase inhibitors also produced a significant (p<0 01) rise in urinary sucrose/lactulose excretion ratios. The relation between dose and response was very different, approximately similar effects being produced by 200 mg BAY g 5421, 100 mg BAY m 1099, and 10 mg BAY 0 1248, giving mean sucrose/lactulose ratios of 0.61 (0.12), 0.58 (0.13), and 0 55 (0.08), respectively (see Fig 2) . Figure 3 shows sucrose/lactulose and lactose/lactulose responses obtained from a single subject receiving nine dose levels of BAY g 5421 (range 10-500 mg). The progressive rise in the sucrose/lactulose excretion ratio shows satisfactory resolution between different levels of ax-glucosidase inhibition while absence of a significant change in lactose/lactulose excretion ratio provides evidence of specificity. Figure 4 shows the rate at which the ct-glucosidase inhibitory action of the three drugs declines. Whereas the sucrose/lactulose excretion ratio after ingestion of BAT g 5421 and BAY m 1099 fall off rapidly, reaching 30% of the initial value when the test dose is delayed by 30 minutes, the effect of BAY o 1248 is more prolonged, taking three hours to reach the 30% level. The resolution obtained seems to be satisfactory for investigating the duration of action of such drugs. Time interval between ingestion of inhibitor and SUC/LAC test solution lactulose, sucrose/lactulose, and palatinose/ lactulose excretion ratios from patients without gastrointestinal disease and patients with untreated and treated coeliac disease. Only the differential urinary excretion of lactose/lactulose from patients with untreated coeliac disease differed significantly (p=0047) from controls.
Eight, one and seven of the coeliac group were found to have varying degrees of defective lactose, sucrose, and palatinose hydrolysis, respectively. The five hour urinary data showed less discrimination (data not shown) between controls and patients with coeliac disease.
In vitro assay ofjejunal biopsy tissue Figure 7 shows the in vitro lactase, sucrase, and palatinase (isomaltase) activities. Figures 5 and 6 and indicate that the sensitivity and precision of the method is adequate to resolve the quantitative differences in dose response and also differences in the duration of disaccharidase inhibition over a short time interval.
Lactosuria and sucrosuria have long been known to occur in patients with coeliac disease29 but the extent to which this was due to increased intestinal (paracellular) permeability or reduced disaccharide hydrolysis has not been clear. '3 30 Blood glucose responses following the conventional lactose tolerance test generally suggest a high prevalence of lactase deficiency in untreated patients,3' but the outcome of this test depends as much upon intestinal monosaccharide transport as upon disaccharidase activity, both of which are often impaired in coeliac disease.3' Changes in monosaccharide absorption may, similarly, interfere with tests that depend upon the rise in blood level or recovery in urine of galactose, of breath '4CO2 derived from ingested '4C-lactulose, and also breath hydrogen, which is generated when either unabsorbed monosaccharide or disaccharide enters the colon.7 8 This problem has usually been solved by repeating the test using an equivalent dose of monosaccharide. In vitro assay of intestinal biopsy tissue usually demonstrates the presence of lactase deficiency in coeliac disease regardless of treatment. 32 The contract between estimates of intestinal disaccharidase activity in coeliac disease by in vitro assay of jejunal tissue and disaccharide hydrolysis assessed in vivo by the disaccharide ratio test is therefore a matter of interest and importance. Ratios of urinary disaccharide excretion, which are not affected by overall variations in monosaccharide transport capacity or permeability to disaccharide, suggest that impairment of intestinal disaccharide hydrolysis may be less prevalent in coeliac disease than suggested by the jejunal disaccharidase assays.
It is of note that although palatinose/lactulose excretion ratios suggest that the in vivo intestinal hydrolysis of palatinose is as efficient as that of sucrose, in vitro assays show that jejunal palatinase activity is much lower than that of sucrase (34 (2) compared with 107 (9) mU/mg protein, respectively). Evidently palatinose is a satisfactory substrate for in vivo assessment of intestinal isomaltase activity but, unlike isomaltose, it seems to exert severe substrate inhibition under the conditions of in vivo assay .33 In summary, the evidence presented suggests that measurement of urinary hydrolysable/nonhydrolysable disaccharide excretion ratios following oral administration of appropriate disaccharides is a reliable non-invasive technique capable of providing simultaneous quantitative assessment of intestinal lactase, sucrase, and isomaltase activity. We have found the method convenient for studying the dose/ response and temporary duration of action of ao-glucosidase inhibitors on sucrose hydrolysis, and for the investigation of lactose hydrolysis in subjects with primary (genetic) adult hypolactasia. A study of patients with coeliac disease shows that in most cases impairment of in vivo disaccharide hydrolysis is only moderate.
